Servier’s $1.55 billion muscular dystrophy drug fails first major test

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.